Encouraging the Alabama Medicaid Agency to evaluate the overall costs of GLP-1 medications and report its findings

HJR 162 is a resolution (not a law) urging the Alabama Medicaid Agency to evaluate the costs and potential savings of covering GLP-1 medications for weight management. It directs the agency to assess whether coverage could save money across the Medicaid program, consider new federal drug pricing models, and consult with providers. The agency must report its findings to the legislature before the 2027 session. This resolution directly affects approximately 110,000 Alabama Medicaid members who might qualify for these medications under current FDA guidelines.